Clinical Trial Search

Primary: Percentage of Patients With at Least a 15-Letter Increase From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye — 6.7; 6.7; 0 Percentage of Patients

Primary: Difference in Mean Number of Ranibizumab Injections — 4.3; 4.1 number of injections — p=0.3680

Primary: Highest Vitreous Humor Level of Brimonidine in the Study Eye — 137.0; 34.9 Nanogram/milliliter (ng/mL)

Primary: Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) Score at 6 Months — 54.7; 56.0; 53.0; 7.3 Units on a scale — p=<0.0001

Primary: Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye — 48.5; 51.0; 52.7; 4.0 Number of Letters Read Correctly

Primary: Number of Participants Experiencing at Least One Adverse Events (AEs) — 13; 7 Participants

Primary: Percentage of Eyes With Anterior Chamber Cell Grade 0 — 65 percentage of eyes

Primary: Mean Change From Baseline in Best-corrected Visual Acuity (BCVA) at Week 52 for the Study Eye — 10.6; 9.4 Scores on a scale — p=<0.001

Primary: Average Change in Best Corrected Visual Acuity (BCVA) From Baseline to Month 1 Through Month 6 — 12.5; 5.0 Letters — p=<0.001

Primary: Change From Baseline in Best-corrected Visual Acuity (BCVA) at Week 52 — 12.2; 11.0 Scores on a scale — p=0.099

Primary: Change From Baseline in Size of Geographic Atrophy Lesion Area in the Study Eye — 6.219; 6.897; 5.526; 0.898 Disc Area

Primary: Change From Baseline in Central Retinal Thickness in the Study Eye — 403.4; -38.9 Microns

Primary: Change From Baseline in Best-corrected Visual Acuity (BCVA) at Week 52 — 7.3; 10.6; 9.2; 10.5 Scores on a scale — p=<0.001

Primary: Percentage of Participants With a ≥2-Step Improvement From Baseline on the Early Treatment Diabetic Retinopathy Study-Diabetic Retinopathy Severity Scale (ETDRS-DRSS) at…

Primary: Mean Number of OZURDEX® Implant Reinjections in the Study Eye — 3.0 number of injections

Primary: Mean Average Best Corrected Visual Acuity (BCVA) Change From Month 1 Through Month 6 to Baseline — 14.9; 10.1 Letters

Primary: Percentage of Patients With a Visual Field Improvement in the Study Eye — 12.0; 9.5; 4.2 Percentage of Patients

Primary: Participants Who Gained at Least 15 Letters in Best Corrected Visual Acuity (BCVA) at Week 24 - LOCF — 24; 48 participants — p=0.0003

Primary: Percentage of Participants With Any Ocular Adverse Events Over the On-treatment Period — 35.0; 23.1 Percentage of participants

Primary: Single-rising Dose (SRD) Part - The Number of Patients With Dose Limiting Events (DLEs) From Drug Administration Until Day 8 — 0; 0; 0 Participants

Primary: Percent Change in Mean Epithelial Cell Density (ECD) — -8.4; -6.8 percentage change in ECD

Primary: Mean Change in Central 1 mm Subfield Thickness Between Baseline and 9 Months — -51; -60 millimeters

Primary: Proportion of Subjects With a >=15 Letter Gain Without a < 5 Letter Loss in Near Visual Acuity — 15; 15; 16 Participants

Primary: Binocular Best Corrected Distance Visual Acuity — -0.05 logMAR

Primary: Vision — 0.16 logMAR

Primary: Time to First Re-treatment — 157 days

Primary: Change From Baseline in Best-corrected Visual Acuity (BCVA) at Week 54 for the Study Eye — 0.2; -4.2 Letters Read — p=<0.001

Primary: Proportion of Subjects With >=15 Letter Gain Without >=5 Letter Loss in Near Visual Acuity — 49.4; 35.0; 22.7 Percentage of participants — p=<.001

Primary: BCVA — 0.8; -0.3; -1.8 Letters

Primary: Mean Intraocular Pressure (IOP) at Each Assessment Timepoint (8 AM, +2 h, +7 h, and +9 h) at Month 3 — 21.1; 22.0; 23.2; 18.0 millimeters mercury (mm HG)